Cantor Fitzgerald analyst Ross Osborn initiated coverage of Anteris Technologies (AVR) with an Overweight rating and $9 price target Anteris is a clinical-stage structural heart company discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis, the analyst tells investors in a research note. Cantor holds a favorable view of the estimated $7.1B transcatheter aortic valve replacement aortic stenosis and valve-in-valve markets and believes Anteris’s DurAVR technology is differentiated from competitors and should serve to drive fast adoption.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue